Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ADXS $7.31 1.7000 +30.30%
RDUS $37.45 5.4200 +16.92%
CRIS $1.31 0.1400 +11.97%
MGNX $38.58 4.0500 +11.73%
FPRX $27.39 1.5000 +5.79%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CALA $23.03 -4.9000 -17.54%
GILD $92.90 -15.5500 -14.34%
ARQL $1.10 -0.0900 -7.56%
EPZM $18.80 -1.1800 -5.91%
PTLA $29.02 -1.6900 -5.50%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 888 | 889 | 890 | 891 | 892 | 893 | 894 | 895 | 896 | 897 | Next > | Last >>

Is Big Pharma Ignoring a Potential Cancer Cure?

(Fox News/LiveScience) May 18, 2011 - On April 12, 1955, the first successful polio vaccine was administered to almost 2 million schoolchildren around the country. Its discoverer, University of Pittsburgh medical researcher Jonas Salk, was interviewed on CBS Radio that evening.
read article 



Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology Are Partnering for Clinical Trials and Compassionate Use Cases in Europe

(Northwest) May 18, 2011 - Northwest Biotherapeutics announced today that it is partnering with Fraunhofer for production of DCVax®-L for brain cancer, for clinical trials and compassionate use cases in Europe.
download pdf 



Welcome to the ASCO Online Summit

(Exelixis) May 17, 2011 - Each spring, we at Exelixis look forward to the Annual Meeting of the American Society of Clinical Oncology (ASCO). As we work towards creating innovative cancer therapies, we see ASCO as an important opportunity to share and discuss our latest results with leaders in the oncology community.
read article  



Bioniche and Endo’s Urocidin Shows Promise in Phase III Bladder Cancer Study

(GEN News) May 18, 2011 - Bioniche Life Sciences and partner Endo Pharmaceuticals claim interim data from an ongoing Phase III trial evaluating Urocidin™ in patients with bacillus Calmett-Guerin (BCG)-refractory nonmuscle invasive bladder cancer (NMIBC) suggest the treatment may represent an alternative to cystectomy.
read article 



At-home Test Could Save Thousands of Lives: Canadian Cancer Society

(Vancouver Sun) May 18, 2011 - An at-home screening test for colorectal cancer could save up to 15,000 lives in the next decade, but few Canadians are aware of the simple test, says the Canadian Cancer Society.
read article 



New Mayo Clinic Test Targets Lynch Syndrome, a Risk Factor for Colon Cancer

(Mayo Clinic) May 18, 2011 - Mayo Clinic has developed a screening procedure that could dramatically increase testing for Lynch syndrome, a hereditary genetic disorder that raises cancer risk, particularly for colorectal cancer.
read press release 



In Rare Skin Cancer, Virus Emerges as Target and Tool

(NCI Cancer Bulletin) May 17, 2011 - After eight pathologists analyzed the tissue, Campbell received a diagnosis: Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer.
read article 



UCSF Team Discovers Key to Fighting Drug-Resistant Leukemia

(UCSF) May 18, 2011 - Doctors who treat children with the most common form of childhood cancer – acute lymphoblastic leukemia – are often baffled at how sometimes the cancer cells survive their best efforts and the most powerful modern cancer drugs.
read press release 



Half of Prostate Cancers Could Potentially Benefit From New Type of Cancer Drugs, U-M Study Finds

(UMHS) May 18, 2011 - About half of prostate cancers have a genetic anomaly that appears to make tumor cells responsive to a new class of cancer-fighting drugs, a new study from the University of Michigan Comprehensive Cancer Center finds.
read press release 



Regulator Wary of Roche's Avastin Ahead of Hearing

(MarketWatch/Dow Jones Newswires) May 18, 2011 - The U.S. Food and Drug Administration's Center for Drug Evaluation and Research, or CDER, reiterated that it doesn't back the use of Roche Holding AG's cancer drug Avastin, slimming the Swiss company's chances of continuing to sell the drug in the U.S. as a treatment for women with advanced breast cancer.
read article 



Males Should Get HPV Vaccine Too, Study Says

(CNN/The Chart Blog) May 18, 2011 - Men also carry the human papillomavirus, the virus that can lead to male cancers and genital warts. And they could spread HPV to their sexual partners, putting those people at risk for cervical cancer.
read article 



Prostate Cancer Risk May Be Reduced by Drinking Coffee, Harvard Study Says

(Bloomberg) May 17, 2011 - Drinking coffee, regular or decaffeinated, may reduce the risk of prostate cancer, according to a study by Harvard University researchers.
read article 



Exelixis Launches Online Summit Featuring Expert Perspectives on Cancer Treatment Advances and ASCO Highlights

(Exelixis) May 18, 2011 - Exelixis, Inc. announced today the launch of its ASCO 2011 Online Summit featuring editorials and perspectives on new cancer therapeutic advances and changing treatment paradigms from scientific, clinical, patient advocacy and industry thought leaders.
read press release 



Myriad Genetics Announces Presentation of Prostate Cancer Study at American Society for Clinical Oncology Annual Meeting

(Yahoo! Finance) May 18, 2011 - Results include survival data based on PROLARIS(TM) analysis of biopsy material.
read article 



OXiGENE Announces Clinical Data From FACT and FALCON Studies to be Presented at ASCO

(Yahoo! Finance) May 18, 2011 - OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that data from its clinical trials of ZYBRESTAT(TM) in combination with chemotherapy in patients with anaplastic thyroid cancer (ATC) and non-small cell lung cancer (NSCLC) will be presented at the upcoming American Society of Clinical Oncology annual meeting in Chicago, Illinois on June 3-7, 2011.
read article 



Bayer To Present Data On Investigational Oncology Compounds At 2011 Annual Meeting Of The American Society Of Clinical Oncology (ASCO)

(TheStreet) May 18, 2011 - Bayer HealthCare Pharmaceuticals, Inc. announced today that data evaluating several of its investigational oncology compounds will be presented in a scientific forum at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7, in Chicago, IL.
read article 



Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting

(Yahoo! Finance) May 18, 2011 - Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced that data evaluating the use of Nexavar® (sorafenib) tablets will be presented in a scientific forum at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7, in Chicago.
read article 



Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting

(Onyx) May 18, 2011 - Onyx Pharmaceuticals, Inc. today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, and ONX 0912, an oral proteasome inhibitor, in hematological cancers at the 47th American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2011 in Chicago, IL.
read press release 



Plexxikon Announces Data Presentations of Oncology Pipeline, Including Phase 3 Vemurafenib Data, at ASCO 2011 Annual Meeting

(Morningstar) May 18, 2011 - Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced that data related to vemurafenib and PLX3397, two promising oncology drugs in its pipeline, will be presented in ten separate presentations at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting taking place June 3 through June 7, 2011 in Chicago, Illinois.
read article 



Cancer Drug Spending to Jump Through 2013: Report

(Reuters) May 18, 2011 - Spending on cancer drugs could rise at least 10 percent a year through 2013, fueled by use of effective -- and expensive -- new therapies used over longer periods, according to a report released on Wednesday.
read article 



Amgen Bone Treatment Shows Promise in Cancer Study

(Forbes/Associated Press) May 17, 2011 - Biotechnology company Amgen Inc. said Tuesday its bone treatment Xgeva outperformed a placebo in a late-stage study of how it works in preventing the spread of advanced prostate cancer to bones.
read article 



Hospice Care Doesn't Hasten Death: Study

(Reuters) May 17, 2011 - Terminally ill patients who opt to receive hospice care won't die any faster as a result of that choice, according to Korean researchers.
read article 



FDA Grants Accelerated Review For Pfizer Cancer Drug

(Morningstar/Dow Jones Newswires) May 17, 2011 - Pfizer Inc. said Tuesday the U.S. Food and Drug Administration will review the company's experimental lung-cancer drug crizotinib on a shortened schedule.
read article 



Roche Touts Personalized Healthcare Approach

(FOX Business/Dow Jones Newswires) May 18, 2011 - Swiss pharmaceuticals company Roche Holding AG Wednesday said that new drug data show that its personalized health care approach is working for patients suffering from skin and lung cancer.
read article 



Phase 3 Data Demonstrate XGEVA(TM) (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer

(Amgen) May 17, 2011 - Amgen today announced primary results of a pivotal Phase 3 trial ('147) demonstrating that XGEVA(TM) (denosumab) significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone. Full results of the '147 study were presented for the first time today in a late-breaking plenary session at the American Urological Association (AUA) 2011 Annual Meeting in Washington, D.C.
read press release